Squalenoyl nanomedicines as potential therapeutics

被引:276
作者
Couvreur, Patrick [1 ]
Stella, Barbara
Reddy, L. Harivardhan
Hillaireau, Herve
Dubernet, Catherine
Desmaele, Didier
Lepetre-Mouelhi, Sinda
Rocco, Flavio
Dereuddre-Bosquet, Nathalie
Clayette, Pascal
Rosilio, Veronique
Marsaud, Veronique
Renoir, Jack-Michel
Cattel, Luigi
机构
[1] Univ Paris Sud, Fac Pharm, CNRS, UMR 8612,IFR 141, F-92296 Chatenay Malabry, France
[2] Univ Turin, Fac Farm, Dipartimento Sci & Tecnol Farm, I-10125 Turin, Italy
[3] Univ Paris Sud, Fac Pharm, CNRS, UMR 8076, F-92296 Chatenay Malabry, France
[4] CEA, Lab Neurovirol, SPI BIO, F-92265 Fontenay Aux Roses, France
关键词
D O I
10.1021/nl061942q
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Nucleoside analogues display significant anticancer or antiviral activity by interfering with DNA synthesis. However, there are some serious restrictions to their use, including their rapid metabolism and the induction of resistance. We have discovered that the linkage of nucleoside analogues to squalene leads to amphiphilic molecules that self-organize in water as nanoassemblies of 100-300 nm, irrespective of the nucleoside analogue used. The squalenoyl gemcitabine exhibited superior anticancer activity in vitro in human cancer cells and gemcitabine-resistant murine leukemia cells, and in vivo in experimental leukemia both after intravenous and oral administration. The squalenoylation of other antiretroviral nucleosides also led to more potent drugs when tested in primary cultures of HIV-infected lymphocytes. Thus, the squalenoylation is an original technology platform for generating more potent anticancer and antiviral nanomedicines.
引用
收藏
页码:2544 / 2548
页数:5
相关论文
共 19 条
  • [1] A PHASE-I CLINICAL, PLASMA, AND CELLULAR PHARMACOLOGY STUDY OF GEMCITABINE
    ABBRUZZESE, JL
    GRUNEWALD, R
    WEEKS, EA
    GRAVEL, D
    ADAMS, T
    NOWAK, B
    MINEISHI, S
    TARASSOFF, P
    SATTERLEE, W
    RABER, MN
    PLUNKETT, W
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (03) : 491 - 498
  • [2] KINETIC-STUDIES ON 2',2'-DIFLUORODEOXYCYTIDINE (GEMCITABINE) WITH PURIFIED HUMAN DEOXYCYTIDINE KINASE AND CYTIDINE DEAMINASE
    BOUFFARD, DY
    LALIBERTE, J
    MOMPARLER, RL
    [J]. BIOCHEMICAL PHARMACOLOGY, 1993, 45 (09) : 1857 - 1861
  • [3] CATTEL L, 1992, ACS SYM SER, V497, P174
  • [4] 2,3-EPOXY-10-AZA-10,11-DIHYDROSQUALENE, A HIGH-ENERGY INTERMEDIATE ANALOG INHIBITOR OF 2,3-OXIDOSQUALENE CYCLASE
    CERUTI, M
    BALLIANO, G
    VIOLA, F
    GROSA, G
    ROCCO, F
    CATTEL, L
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1992, 35 (16) : 3050 - 3058
  • [5] Nucleoside analogues: mechanisms of drug resistance and reversal strategies
    Galmarini, CM
    Mackey, JR
    Dumontet, C
    [J]. LEUKEMIA, 2001, 15 (06) : 875 - 890
  • [6] GEMCITABINE IN LEUKEMIA - A PHASE-I CLINICAL, PLASMA, AND CELLULAR PHARMACOLOGY STUDY
    GRUNEWALD, R
    KANTARJIAN, H
    DU, M
    FAUCHER, K
    TARASSOFF, P
    PLUNKETT, W
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (03) : 406 - 413
  • [7] HEINEMANN V, 1992, CANCER RES, V52, P533
  • [8] HERTEL LW, 1990, CANCER RES, V50, P4417
  • [9] SYNTHESIS OF 2-DEOXY-2,2-DIFLUORO-D-RIBOSE AND 2-DEOXY-2,2-DIFLUORO-D-RIBOFURANOSYL NUCLEOSIDES
    HERTEL, LW
    KROIN, JS
    MISNER, JW
    TUSTIN, JM
    [J]. JOURNAL OF ORGANIC CHEMISTRY, 1988, 53 (11) : 2406 - 2409
  • [10] Japour A J, 1995, AIDS Clin Care, V7, P63